Copernicus SOCT receives FDA clearance

March 19, 2008

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

The Copernicus is designed for in vivo imaging and measurement of the retina by using spectral tomography to rapidly create high-resolution images of retinal structures. These detailed three-dimensional images enhance a physician's ability to diagnose and monitor retinal disease and perform pre- and post procedural assessments of patients.

The SOCT was the first commercially available device on the world market.